|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Thursday
NeuroVax: Immune Response Corporation Receives $9.9 Million...Raising Aggregate $17.9 Million from 2006 Financing:
"Funding Will Support Continuation of Phase II Clinical Trials In MS. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS..." |